OBJECTIVES: Aortic valve replacement (AVR) using sutureless technology is a feasible alternative in surgical patients. Comparative evidence against established strategies such as conventional AVR and transcatheter AVR is lacking, limiting the assessment of safety and efficacy.
INTRODUCTION
Surgical aortic valve replacement (AVR) has been the gold standard in low-and intermediate-risk patients affording correction of annular pathology under direct vision and is associated with low morbidity and mortality [1] . Treatment of high-risk patients is an area of increasing interest due to the ageing population sustaining better outcomes. The results of the past 2 years of the PARTNER trial cohort A [patients with an intermediate-high risk and the Society of Thoracic Surgeons (STS) risk score >8% (mean STS above 11) randomized to conventional aortic valve replacement (conAVR) or transcatheter aortic valve replacement (TAVR)] suggest non-inferiority of TAVR versus conAVR but association with higher rates of paravalvular leak (PVL) and adjusted mortality [2] . In addition, the 5-year PARTNER cohort B results suggested almost 20% risk reduction among inoperable patients in favour of TAVR versus standard therapy [3] . Proponents of TAVR suggest a new paradigm shift [4] in favour of TAVR, but real-life practice involves 'grey areas' such as suboptimal peripheral access, porcelain aorta, bicuspid valves and requirement for concomitant procedures for which TAVR or conAVR may not be suitable. Novel technologies such as the sutureless Perceval S (Sorin Group, Saluggia, Italy) or the Edwards INTUITY valve (Edwards Lifesciences, Irvine, CA, USA) implantation either via a standard or a minimally invasive approach have afforded reduction in cardiopulmonary bypass (CPB) and ischaemic times, low mortality (30-day overall mortality 3.7% and valve-related mortality 0.5%) and a low risk for stroke [5] . In addition, sutureless technology has demonstrated feasibility in small aortic root [6] , porcelain aorta [7] and bicuspid aortic valve [8] .
For any novel technology to be accepted for wider use, its safety needs to be scrutinized against conventional AVR (stented or stentless bioprostheses) and TAVR technology in methodologically rigorous evidence assessment. The authors have considered two objectives: first to ascertain the safety of sutureless aortic valve replacement (SU-AVR) by undertaking a systematic assessment of evidence if used as a substitute to conventional surgical (stented or stentless bioprostheses) or against the TAVR population and secondly to establish the statistical reliability of accumulated evidence by undertaking trial sequential analyses (TSAs).
METHODS
A prespecified protocol was developed and adhered to the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines [9] .
Study identification, search and data collection
Published studies (observational or randomized) comparing sutureless versus conAVR using a stented or stentless valve or versus TAVR (any prosthesis/approach) were included. Noncomparative studies, reviews, how-to-do articles, feasibility and animal studies were excluded.
The primary outcome was 30-day mortality, whereas the secondary outcomes were in-hospital measured outcomes such as acute kidney injury (AKI)/renal replacement therapy (RRT), myocardial infarction (MI), cerebrovascular accident (CVA), intensive care unit (ICU) stay and hospital stay, PVL, need for permanent pacemaker (PPM), CPB time and ischaemic (cross-clamp) time. A search was undertaken using electronic databases (Medline and Embase) from inception to January 2016 using prespecified key words and restricted to the English language. Several keyword combinations were trialled, but the keyword combination [(sutureless) AND (aortic) AND (valve)] retrieved the most pertinent results. Further hand search was carried out on a bibliography list of included studies for potentially relevant studies.
Assessment of methodological quality
The randomized controlled trial (RCT) was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (http://www.gradewor kinggroup.org/), where risk of bias (ROB) was used to guide whether the trials had limitations. The quality of observational studies was assessed using the STrengthening the Reporting of OBservational studies in Epidemiology [STROBE checklist, https:// www.strobe-statement.org/ (13 August 2017, date last accessed)]. Detailed methodology and interpretation are provided in Supplementary Material, Methods.
Data analysis
Dichotomous outcomes (30-day mortality, CVA, MI, incidence of AKI/RRT, PVL and the need for PPM) have been presented as odds ratios (OR) with 95% confidence intervals (CIs) using the Peto fixed-effect model followed by significance for effect estimate (P), I 2 statistic and its significance (P) and number of events (n) in intervention (I)/total sample (N):number of events in control (C)/total sample (N). If significant heterogeneity was found, a random-effect model using the Mantel-Haenszel method was also used. Pooling of continuous outcomes (ICU stay, hospital stay, CPB time and ischaemic time) was done as weighted mean differences and presented as mean differences with 95% CI using the inverse variance method followed by significance for effect estimate (P), I 2 statistic and its significance (P) and sample (N) in intervention/sample in control (C). ICU stay and hospital stay are pooled and described in days and CPB and cross-clamp times in minutes.
Heterogeneity was assessed with I 2 statistics, and I 2 value > _50% was considered to be substantial. Publication bias was evaluated for the presence or absence of visual asymmetry on funnel plots. A sensitivity analysis was undertaken according to the predicted operative risk to stratify outcomes. Operative risk was defined according to the logistic EuroSCORE as low (<10%), intermediate (10% to < 20%) and high (>20%) and/or the STS score as low (<3), intermediate (>3 to <8) and high (>8). All analyses were carried out using Review Manager (RevMan), Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. Forest plots for primary, subgroup and sensitivity analyses are provided in the Supplementary Material.
Trial sequential analyses
Because of paucity of the included studies, there was a risk that current meta-analyses would be under-powered. TSA was applied to improve the validity of results by adjusting for insufficient information size [10, 11] . We undertook TSAs of primary (30-day mortality) and secondary outcomes (CVA, acute renal failure/RRT, risk of PPM implantation and PVL) in both SU-AVR versus conAVR and SU-AVR versus TAVR comparisons using data derived from propensity-matched studies only. The selected primary and secondary outcomes were chosen based on clinical significance. As described previously [10] , TSA output was analysed for evidence of effect, absence of evidence, potentially spurious evidence of effect or firm evidence of effect. TSA viewer version 0.9 b, Copenhagen Trial Unit 2011, Denmark, was used for TSA [www.ctu.dk/tsa (13 August 2017, date last accessed)].
Further details on TSA methodology is provided in Supplementary methods.
RESULTS

Characteristics of included studies and risk of bias
A PRISMA flow diagram depicting the overall search strategy is provided in Fig. 1 . A total of 11 observational studies and 1 RCT were included. Important characteristics such as sample size, period of implantation, declared conflict of interest, predicted risk for mortality, STROBE scores, method of definitions for clinical outcomes and outcomes by treatment arm are detailed in the Supplementary Material, Table S1 .
The studies considered for SU-AVR versus conAVR comparison comprised Gilmanov et al. [12] , Pollari et al. [13] , Dalen et al. [14] , Muneretto et al. [15] , D'Onforio et al. [16] , Borger et al. [17] , Vola et al. [18] and Shrestha et al. [6] , whereas the studies considered for SU-AVR versus TAVR comparison included Biancari et al. [19] , Miceli et al. [20] , Muneretto et al. [15] , D'Onofrio et al. [16] , Kamperidis et al. [21] and Santarpino et al. [22] . Potential overlapping studies were from Gilmanov et al. [12] and Miceli et al. [20] as both originated from a single centre; however, their data were pooled for separate comparisons. Similarly, studies from Pollari et al. [13] and Santarpino et al. [22] originated from a single institution but were included in separate comparisons. Potential overlap was assessed between studies from Santarpino et al. [22] and Biancari et al. [19] as they reported a similar comparison (SU-AVR versus TAVR); however, source institution was different for the TAVR experience (Paracelus Medical University, Nuremberg, Germany, versus Ferrarotto Hospital, University of Catania, Italy). Another potential overlap was analysed between Dalen et al. [14] and Pollari et al. [13] for the comparison of SU-AVR versus conAVR. The authors and institutions for both studies were similar, but each reported outcomes in different populations (i.e. Pollari et al. 2014 [13] , SU-AVR: N = 166, conAVR: N = 400; Dalen et al. 2015 [14] , SU-AVR: N = 182, conAVR: N = 383; hence, a sensitivity analysis was carried out after removing data extracted from Pollari et al. [13] for the outcomes of mortality, AKI/RRT, risk for PVL, requirement for PPM, ICU stay and hospital length of stay and cross-clamp and CPB times in the comparison with SU-AVR versus conAVR). Pollari et al. [13] was excluded preferentially to Dalen et al. [14] as the latter had wider published experience.
The sutureless valve was implanted using the Sorin Perceval S valve in 8 studies [6, 12-16, 19, 20, 22] , the 3F-Enable valve in 2 studies and the Edwards INTUITY valve (rapid deployment) in 1 study; however, a single study used a combination of all 3 valves [12] . A minimally invasive approach was utilized by 5 studies [12, 14, 17, 18, 20] , and a combined practice was displayed by 6 studies [6, 13, 15, 16, 19, 22] . Mortality was described as in-hospital in 4 studies [12, 19, 20, 22] and as 30 days in 8 studies [6, [13] [14] [15] [16] [17] [18] 21] and hence analysed as 30-day mortality only. Studies considered in the operative risk category include (low) Dalen [16] . No high-risk studies appropriate for analyses were available (e.g. high-risk populations in both intervention and control arms). The single included RCT [17] was assessed using GRADE criteria and found to have 'high' ROB and hence categorized as 'GRADE-limited'. As methodological rigor for the control of selection and performance bias was not established with this single RCT, it was considered among unmatched outcome analyses in SU-AVR versus conAVR comparisons. The mean STROBE compliance score was 48% (range 42-57%). The scores for individual studies are shown in the Supplementary Material, Table S1 , with detailed assessment in Fig. 2 
Effects of interventions Sutureless aortic valve replacement versus transcatheter aortic valve replacement
Mortality. Six studies with 1228 participants were included.
The STROBE scores ranged from 43% to 50%. The analysis of matched studies [15, 16, [19] [20] [21] [22] displayed benefit vis-à -vis 30-day mortality in favour of SU-AVR [OR (95% CI), P-value (effect estimate), P-value (heterogeneity)]: 0.40 (0.25, 0.62), P < 0.001, I Table S3 ). No publication bias was observed on visual inspection of funnel plots (Supplementary Material, Fig. S1A ). Sensitivity analyses undertaken on propensity-matched data grouped according to the predicted risk, i.e. low [12, 14, 17, 18, 19] and intermediate [13, 15, 16, [20] [21] [22] Acute kidney injury/need for renal replacement therapy. Five studies with 1024 participants were included. The STROBE scores ranged from 43% to 50%. The analysis of matched studies [15, 16, [19] [20] [21] was not significant [0.80 (0.49, 1.32), P = 0.39; n/N, I:C: 31/456:43/568]; however, unadjusted outcome analysis (single study, n = 794, STROBE score 43%) showed renoprotection using TAVR [3.17 (1.10, 9.12), P = 0.03; n/N, I:C:11/ 397:3/394] (Fig. 3) [19] . The effect estimates were affected by substantial heterogeneity that persisted despite using the random-effect model (I 2 : 62%, P = 0.03). TSA revealed 'lack of evidence' to either support or refute that SU-AVR is associated with RRR versus TAVR and more studies are needed (Supplementary Material, Table S4 ).
Myocardial infarction and cerebrovascular accident. Six studies with 1228 participants were included for the assessment of risk for CVA and 2 studies (n = 582) for the risk for MI; STROBE 2 : 0%; n/N, I:C: 1/235:9/347 [15, 16] ; (Fig. 3) ] or unadjusted outcomes for CVA (single study, n = 794, STROBE score 43%: 1.77 (0.62, 5.10), P = 0.29, I
2 : not applicable; n/N, I:C:9/397:5/394) [19] . No studies were available to undertake unadjusted analyses of the risk for MI. TSA revealed 'lack of evidence' to either support or refute that SU-AVR is associated with RRR versus TAVR and more studies are needed (Supplementary Material, Table S4 ).
Requirement for permanent pacemaker and risk for paravalvular leak.
Six studies with 1228 participants (STROBE score 43-50%) were available for the assessment of PPM and the risk for PVL. Of the 6 studies, 5 used the Perceval S valve, whereas 1 study utilized the 3F-Enable valve with the risk of PPM: 3.2% [16] , 5.4% [21] , 9.8% [15] , 10% [22] , 11.2% [19] and 2.5% [21] . Adjusted (matched) outcomes were not significant for risk of PPM [0.74 (0.50, 1.08), P = 0.12, [19] . There was 'absence of evidence' to either support or refute that SU-AVR is associated with RRR of PPM implantation versus TAVR; however, 'firm evidence of effect' for at least 30% RRR of PVL with SU-AVR versus TAVR was established in TSA analyses (Supplementary Material, Table S4 ). Intensive care unit and hospital stay (days). A single propensity-matched study (n = 204, STROBE score 48%) [22] (Fig. 3) .
Sutureless aortic valve replacement versus conventional aortic valve replacement
Mortality. Five studies [12] [13] [14] [15] [16] (n = 1323, STROBE compliance score; 43-50%) were included in propensity-matched, 3 studies in unmatched (n = 768, STROBE score 42-55%) [6, 14, 18] TSAs were undertaken at each prespecified RRR of 10-50%. TSA showed the 'absence of evidence' for SU versus conAVR comparison due to lack of effect. More studies, however, are required to show conclusive 'presence' or 'absence' of effect for this comparison ( Fig. 8 ; Supplementary Material, Table S3 ). There was evidence of publication bias on visual inspection of funnel plot ( Supplementary  Material, Fig. S1B ). Exclusion of Pollari et al. [13] did not alter the non-significance of primary analysis (Supplementary Material, Table S6 ). Sensitivity analyses undertaken on propensitymatched data grouped according to the predicted risk, i.e. low [12, 14] and intermediate [13, 15, 16] , did not alter the results of primary analyses. No suitable studies affording high-risk comparative analyses (i.e. intervention and control arms both being at high risk) were feasible (Supplementary Material, Fig. S3 and Table S5 ).
Acute kidney injury/need for renal replacement therapy. Two studies (n = 551, STROBE score 43%, 50%) were available for propensity-matched analyses [15, 16] and single RCT [17] . Table S4 ).
Myocardial infarction and cerebrovascular accident.
Three matched (n = 817, STROBE score 43-50%) [12, 15, 16 ] and 1 RCT [17] (n = 94, GRADE 'limited'; based on positive qualifying features of serious ROB) were evaluated for the assessment of risk for MI, whereas 5 adjusted [12] [13] [14] [15] [16] (n = 1323, STROBE compliance score 43-50%) and 1 RCT [17] and 2 observational studies [14, 18] (n = 648, STROBE score 42 and 55%) were assessed for the risk for stroke. The effect estimates were non-significant, 1.22 (0.24, 6.35), P = 0.81, I Table S4 ). Exclusion of Pollari et al. [13] did not alter the lack of significance of primary analysis (Supplementary Material, Table S6 ).
Requirement for permanent pacemaker and risk for paravalvular leak. Five matched studies [12] [13] [14] [15] [16] (n = 1323, STROBE compliance score 43-50%) and 2 unadjusted studies The X-axis indicates the cumulative number of patients (i.e. 2714). Starting point of the z-curve (blue line) is always at x = 0, i.e. inclusion of no studies. Horizontal brown line depicts conventional boundary (Alpha; P = 0.05), whereas the funnel-shaped outer boundary represents trial sequential analyses adjusted boundaries calculated according to the O'Brien-Fleming alpha-spending function. Vertical line towards the right of the graph shows trial sequential analyses-adjusted required information size. The small triangle towards the right represents futility zone; futility is the proof of no effectiveness (i.e. demonstration of both non-superiority and non-inferiority). The intervention effect was set as RRR of 30%, a = 0.05 (2 sided) and b = 0.20 (power 80%). RRR: relative risk reduction; SU-AVR: sutureless aortic valve replacement; TAVI: transcatheter aortic valve implantation. [14, 18] (n = 648, STROBE score 42% and 55%) and 1 RCT [17] were analysed for the risk of PPM, whereas 4 matched [12, 13, 15, 16] (n = 1057, STROBE score 42-50%) and 3 unadjusted studies [6, 14, 18] (n = 768, STROBE score 42-57%) and 1 RCT [17] were analysed for the risk for PVL. All 5 matched studies in this analysis utilized the Perceval S valve with reported incidence: 3.2% [16] , 4.5% [12] , 6.1% [13] , 9.8% [15] and 9.9% [14] . Risk of PPM was significantly less with conAVR in matched and unadjusted analyses: 2.16 (1.34, 3.47), P = 0.002, I
2 : 16%, P = 0.31; n/N, I:C: 49/621:24/702 (Fig. 6 ) and 5.72 (2.65, 12.36), P < 0.001, I 2 : 63%, P = 0.04] (Fig. 6 ) and 0.77 (0.41, 1.47), P = 0.43, I 2 : 59%, P = 0.06; n/N, I:C: 15/319:27/543. Potentially 'spurious evidence of effect' existed for SU-AVR versus conAVR comparison for risk of PPM implantation, and 'too little information' was available to deduce the risk for PVL (Supplementary Material, Table S4 ) using TSA. Exclusion of Pollari et al. [13] did not alter the results of primary analysis (Supplementary Material, Table S6 ).
Intensive care unit and hospital stay (days). Three matched [13] [14] [15] (n = 914, STROBE score 42-48%) as well as 3 unadjusted studies [6, 14, 18] (n = 768, STROBE score 42-57%) for ICU stay, 1 matched [13] (n = 164, STROBE score 48%) and another single unadjusted study (n = 120, STROBE score 57%) [6] were analysed for hospital stay. The analyses were as follows: matched analyses: ICU stay, 0.11 (-0.17, 0.38), P = 0.44, I
2 : 79%, P = 0.010, N:I/C: 457/457 ( [13] did not alter the results for ICU stay. Post exclusion, the effect on hospital stay could not be inferred due to lack of studies (Supplementary Material, Table S6 ).
DISCUSSION
This meta-analysis attempted to evaluate evidence with the aim to appraise clinicians on the quality and direction of available evidence. The key findings are that SU-AVR is associated with 30% reduction in relative risk for PVL and 30-day mortality compared with TAVR. The effect of SU-AVR on 30-day mortality versus conAVR requires further evidence. There is also 'firm evidence' to implicate sutureless technology associated with the increased risk of PPM compared with conAVR.
The current meta-analysis has several strengths. The review used a comprehensive search strategy, contemporary ROB assessments (GRADE for randomized studies and STROBE assessment for observation studies) and assessed clinically relevant outcomes. Both propensity-matched (bias adjusted) and unadjusted (real-world data) evidence were pooled separately. Type I error associated with multiple significant testing that often plagues meta-analyses was controlled using TSAs, and the effect estimates were validated. Furthermore, we assessed publication bias and adjusted heterogeneity. Although there is no consensus on the level of intervention effect, we assumed a liberal range of 10-50% RRR that we believe controls for inherent risk for overestimation of the effect estimates with sequential design analyses [23] .
The current finding of mortality benefit with SU-AVR versus TAVR is corroborated by other reviewers [24] . However, it is debatable that this benefit could be short term and not long term as suggested by some [24] . Nonetheless, the finding of associated increased risk for PVL is likely the cause of increased mortality in TAVR group. This is due to lack of annular decalcification or suboptimal inflation of balloon accounting for an incidence of up to 85% [25] and independently associated with increased mortality [26] . This could also explain why there is no difference in mortality between SU and conAVR as both effectively address the source of PVL. Despite the use of newer generation balloon-expandable devices in the recent PARTNER cohort A trial and showing noninferiority of TAVR versus conAVR, the 2-year risk for moderatesevere PVL was still lower in the conAVR group (0.6% vs 8%) [2] .
The risk of PPM with SU-AVR is a cause for concern acknowledged by others [27] and supported by our findings and, hence, fuels the argument that self-expanding and rapid-deployment valve implantation may exert differential stresses on the annulus. These stresses likely get perpetuated with time or a non-linear relationship exists in the forces required to dilate the valve prostheses of certain diameters than others [28] . The balance of radial expansion forces and annular deformation responses are further at risk in the case of severe calcification or friable aortas of elderly recipients.
Limitations
The limitations of this study would be lack of separate subgroup analyses for minimally invasive versus full sternotomy and isolated versus concomitant procedures; however, this had the potential of leaving even smaller data sets for subgroup analyses with the risk of Type II error and data mining. Nonetheless, these could be important confounders, and the results should be judged with caution. Furthermore, there are significant limitations with available evidence, i.e. lack of methodological rigor (11 of the included studies being observational and single included RCT afflicted with GRADE 'limitation').
Implications for clinical practice
Recent expert consensus supports the use of sutureless technology in patients with isolated or concomitant procedures where controlling CPB comorbidity is imperative and in calcified root, porcelain aorta as well as prior implantation of aortic homograft [29] . Acknowledging the limitations of current evidence, this meta-analysis advocates selected patients with worse annular characteristics and higher inherent risk for PVL to be offered SU-AVR and not TAVR. Neither superiority nor inferiority can be firmly established against conAVR. It is our recommendation that the safety and efficacy of sutureless and rapid-deployment technology should be further tested in large-scale randomized trials controlling annular characteristics beyond other variables against both TAVR and conAVR.
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